The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A single-arm, open-label, phase 2 study evaluating pacritinib for patients with biochemical recurrence after definitive treatment for prostate cancer: Blast study.
 
Deepak Kilari
Honoraria - Exelixis
Consulting or Advisory Role - Exelixis; Merck Sharp & Dohme; Myovant Sciences; Sanofi
Speakers' Bureau - Astellas Pharma; Exelixis; Genzyme; Genzyme (Inst); Janssen
Research Funding - Astellas Pharma (Inst); Exelixis (Inst); Genentech (Inst)
Travel, Accommodations, Expenses - Bayer; Clovis Oncology; Exelixis; Janssen; Sanofi
 
Aniko Szabo
No Relationships to Disclose
 
William A. Hall
Research Funding - Elekta (Inst)
Travel, Accommodations, Expenses - Elekta (Inst)
 
Ariel Ann Nelson
No Relationships to Disclose
 
Scott Johnson
No Relationships to Disclose
 
Thomas A. Giever
No Relationships to Disclose
 
John Burfeind
No Relationships to Disclose
 
Parag Tolat
No Relationships to Disclose
 
Kathryn A. Bylow
No Relationships to Disclose
 
Kenneth Iczkowski
No Relationships to Disclose
 
Yunguang Sun
No Relationships to Disclose
 
Hallgeir Rui
No Relationships to Disclose
 
James P. Thomas
No Relationships to Disclose
 
Marja Nevalainen
No Relationships to Disclose